RE:RE:RE:RE:Does it really matter?
As much as I respect your opinion, I have to disagree with you on this one Stocktree.
Maybe retail doesn't have much of a clue, but I can guarantee you all eyes are on this in the investment community.
The biggest reason it will pass FDA assume the data is good is there are no negative side effects.
Yes, the treatment is going to be limited to those with specific MOD scores. It's a targeted treatment, they've already indicated that. It will be used for those whom is has shown to be most effective. The only exception may be deep pocket patience that choose to pay the cost on their own. Hosptals will not allow the expense on those who may have little benefit.
IMHO .... top line data will be a golden ticket. If it's weak data, then it becomes a gamble.
If we are 20% or over in absolute benefit we are good to go. If it's under that, we wlll have to wait for FDA in March / April.